Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2791-2800 Newer>

Managed Care March 2006	Standard Measures In Works For P4P Push Uncle Sam has decided to get behind the pay-for-performance effort in a big way, something some physician associations are less than thrilled about.
Managed Care March 2006	HMOs Want Evidence About Arthritis Drugs Long-term research needs to be done on the cost effectiveness of biologics in fighting rheumatoid arthritis before health plans can be convinced that coverage of the new agents will save money in the long run, a recent study suggests.
Managed Care March 2006	Cigna Offers Quick Care At Retail Outlets Cigna hopes to marry convenience to cost effectiveness with a new benefit package that covers enrollees who get treatment for common ailments at MinuteClinic health care centers.
Managed Care March 2006	Health Costs Expected To Hit $4 Trillion in 2015 The amount the U.S. spends on health care will reach $4 trillion, or about 20 percent of gross domestic product in 2015, according to a report by the National Health Statistics Group, a division of the Centers for Medicare & Medicaid Services.
Managed Care March 2006 Michael S. Victoroff	When Should Bad Behavior Become a Covered Disease? Defining noxious people as 'sick' distinguishes them socially from sinners, criminals, and scoundrels.
Managed Care March 2006	Compensation Monitor Higher salaries go to clinical executives who hold business degrees.
Managed Care March 2006 Thomas Morrow	Sharp Strategy Needed with New Treatment Options for PAH As another treatment for pulmonary hypertension nears approval, insurers should adopt a stepped-care approach.
The Motley Fool March 30, 2006 David Compton	Glaxo's New Flu-Fighting Ammo The FDA certifies the drugmaker's Relenza for defense as well as offense. For investors seeking to give their portfolios a shot in the arm, now might be the time to take a closer look at Glaxo.
The Motley Fool March 29, 2006 Stephen D. Simpson	Novartis Bulks Up Its Pipeline The Swiss drug giant once again pays up to add trial candidates to its portfolio. Investors, take note.
The Motley Fool March 28, 2006 Stephen D. Simpson	A Surprising Turn at Biomet The large orthopedic company replaces one of its founders. This change doesn't really make the stock dramatically more, or less, attractive than before. Investors, take note.
<Older 2791-2800 Newer> Return to current articles.